 |
|
|
|
|
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Koldamova R, Lefterov I. on PAPER: Lee JH. et al., 2009, In this article, Lee et al. examine the mechanism by which Liver X Receptors (LXRα /b) inhibit... 30 Sep 2009.
|
|
|
 |
|
|
Koldamova R. on NEWS: ApoE’s Secret Revealed? Protein Promotes Aβ Degradation, The inheritance of ApoE ε4 is so far the only discovered risk factor for late-onset AD, but the... 17 Jun 2008.
|
|
|
|
|
|
Koldamova R. on PAPER: Kim HJ. et al., 2008, This study by Kim et al. extends the Gustafsson group’s previous work on the role of nuclear... 5 Feb 2008.
|
|
|
|
|
|
Koldamova R. on PAPER: Liu Q. et al., 2007, The study by Liu et al. shines a new light on the connection between cholesterol metabolism and... 10 Oct 2007.
|
|
|
|
|
|
Koldamova R, Lefterov I. on NEWS: Hearts and Minds: Can Both Benefit From Cholesterol Pathway Fix?, The paper by Zelcer and coauthors (1) comes from a leading laboratory in the field of LXR... 21 Jun 2007.
|
|
|
|
|
|
Koldamova R, Lefterov I. on NEWS: ABCA1 Loss Lowers ApoE, Not Amyloid; New ApoE Immunology, In our study, we used APP23 transgenic mice in which human familial Swedish AD mutant is... 21 Oct 2005.
|
|
|
|
|
|
Koldamova R, Lefterov I. on NEWS: ABCA1 Loss Lowers ApoE, Not Amyloid; New ApoE Immunology, The newly proposed role for ApoE in lipid antigen presentation reported by van den Elzen et al.... 21 Oct 2005.
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
